Hidde Heesakkers1, Johannes G van der Hoeven1, Stijn Corsten2, Inge Janssen3, Esther Ewalds4, Koen S Simons5, Brigitte Westerhof6, Thijs C D Rettig7, Crétien Jacobs8, Susanne van Santen9, Arjen J C Slooter10,11, Margaretha C E van der Woude12, Mark van den Boogaard1, Marieke Zegers1. 1. Radboud University Medical Center, Radboud Institute for Health Sciences, Department Intensive Care, Nijmegen, the Netherlands. 2. Department of Intensive Care Medicine, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands. 3. Department of Intensive Care Medicine, Maasziekenhuis Pantein, Beugen, the Netherlands. 4. Department of Intensive Care Medicine, Bernhoven Hospital, Uden, the Netherlands. 5. Department of Intensive Care Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands. 6. Department of Intensive Care Medicine, Rijnstate Hospital, Arnhem, the Netherlands. 7. Department of Anesthesiology, Intensive Care and Pain Medicine, Amphia Hospital, Breda, the Netherlands. 8. Department of Intensive Care Medicine, Elkerliek Hospital, Helmond, the Netherlands. 9. Department of Intensive Care Medicine, Maastricht University Medical Center, Maastricht, the Netherlands. 10. Department of Intensive Care Medicine and UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands. 11. Department of Neurology, UZ Brussel and Vrije Universiteit Brussel, Brussels, Belgium. 12. Department of Intensive Care and Department of Quality and Safety, Heerlen Medical Center, Heerlen, the Netherlands.
Abstract
IMPORTANCE: One-year outcomes in patients who have had COVID-19 and who received treatment in the intensive care unit (ICU) are unknown. OBJECTIVE: To assess the occurrence of physical, mental, and cognitive symptoms among patients with COVID-19 at 1 year after ICU treatment. DESIGN, SETTING, AND PARTICIPANTS: An exploratory prospective multicenter cohort study conducted in ICUs of 11 Dutch hospitals. Patients (N = 452) with COVID-19, aged 16 years and older, and alive after hospital discharge following admission to 1 of the 11 ICUs during the first COVID-19 surge (March 1, 2020, until July 1, 2020) were eligible for inclusion. Patients were followed up for 1 year, and the date of final follow-up was June 16, 2021. EXPOSURES: Patients with COVID-19 who received ICU treatment and survived 1 year after ICU admission. MAIN OUTCOMES AND MEASURES: The main outcomes were self-reported occurrence of physical symptoms (frailty [Clinical Frailty Scale score ≥5], fatigue [Checklist Individual Strength-fatigue subscale score ≥27], physical problems), mental symptoms (anxiety [Hospital Anxiety and Depression {HADS} subscale score ≥8], depression [HADS subscale score ≥8], posttraumatic stress disorder [mean Impact of Event Scale score ≥1.75]), and cognitive symptoms (Cognitive Failure Questionnaire-14 score ≥43) 1 year after ICU treatment and measured with validated questionnaires. RESULTS: Of the 452 eligible patients, 301 (66.8%) patients could be included, and 246 (81.5%) patients (mean [SD] age, 61.2 [9.3] years; 176 men [71.5%]; median ICU stay, 18 days [IQR, 11 to 32]) completed the 1-year follow-up questionnaires. At 1 year after ICU treatment for COVID-19, physical symptoms were reported by 182 of 245 patients (74.3% [95% CI, 68.3% to 79.6%]), mental symptoms were reported by 64 of 244 patients (26.2% [95% CI, 20.8% to 32.2%]), and cognitive symptoms were reported by 39 of 241 patients (16.2% [95% CI, 11.8% to 21.5%]). The most frequently reported new physical problems were weakened condition (95/244 patients [38.9%]), joint stiffness (64/243 patients [26.3%]) joint pain (62/243 patients [25.5%]), muscle weakness (60/242 patients [24.8%]) and myalgia (52/244 patients [21.3%]). CONCLUSIONS AND RELEVANCE: In this exploratory study of patients in 11 Dutch hospitals who survived 1 year following ICU treatment for COVID-19, physical, mental, or cognitive symptoms were frequently reported.
IMPORTANCE: One-year outcomes in patients who have had COVID-19 and who received treatment in the intensive care unit (ICU) are unknown. OBJECTIVE: To assess the occurrence of physical, mental, and cognitive symptoms among patients with COVID-19 at 1 year after ICU treatment. DESIGN, SETTING, AND PARTICIPANTS: An exploratory prospective multicenter cohort study conducted in ICUs of 11 Dutch hospitals. Patients (N = 452) with COVID-19, aged 16 years and older, and alive after hospital discharge following admission to 1 of the 11 ICUs during the first COVID-19 surge (March 1, 2020, until July 1, 2020) were eligible for inclusion. Patients were followed up for 1 year, and the date of final follow-up was June 16, 2021. EXPOSURES: Patients with COVID-19 who received ICU treatment and survived 1 year after ICU admission. MAIN OUTCOMES AND MEASURES: The main outcomes were self-reported occurrence of physical symptoms (frailty [Clinical Frailty Scale score ≥5], fatigue [Checklist Individual Strength-fatigue subscale score ≥27], physical problems), mental symptoms (anxiety [Hospital Anxiety and Depression {HADS} subscale score ≥8], depression [HADS subscale score ≥8], posttraumatic stress disorder [mean Impact of Event Scale score ≥1.75]), and cognitive symptoms (Cognitive Failure Questionnaire-14 score ≥43) 1 year after ICU treatment and measured with validated questionnaires. RESULTS: Of the 452 eligible patients, 301 (66.8%) patients could be included, and 246 (81.5%) patients (mean [SD] age, 61.2 [9.3] years; 176 men [71.5%]; median ICU stay, 18 days [IQR, 11 to 32]) completed the 1-year follow-up questionnaires. At 1 year after ICU treatment for COVID-19, physical symptoms were reported by 182 of 245 patients (74.3% [95% CI, 68.3% to 79.6%]), mental symptoms were reported by 64 of 244 patients (26.2% [95% CI, 20.8% to 32.2%]), and cognitive symptoms were reported by 39 of 241 patients (16.2% [95% CI, 11.8% to 21.5%]). The most frequently reported new physical problems were weakened condition (95/244 patients [38.9%]), joint stiffness (64/243 patients [26.3%]) joint pain (62/243 patients [25.5%]), muscle weakness (60/242 patients [24.8%]) and myalgia (52/244 patients [21.3%]). CONCLUSIONS AND RELEVANCE: In this exploratory study of patients in 11 Dutch hospitals who survived 1 year following ICU treatment for COVID-19, physical, mental, or cognitive symptoms were frequently reported.
Authors: Alyaa Elhazmi; Awad Al-Omari; Hend Sallam; Hani N Mufti; Ahmed A Rabie; Mohammed Alshahrani; Ahmed Mady; Adnan Alghamdi; Ali Altalaq; Mohamed H Azzam; Anees Sindi; Ayman Kharaba; Zohair A Al-Aseri; Ghaleb A Almekhlafi; Wail Tashkandi; Saud A Alajmi; Fahad Faqihi; Abdulrahman Alharthy; Jaffar A Al-Tawfiq; Rami Ghazi Melibari; Waleed Al-Hazzani; Yaseen M Arabi Journal: J Infect Public Health Date: 2022-06-17 Impact factor: 7.537
Authors: Kapil Nanwani-Nanwani; Lorenzo López-Pérez; Carola Giménez-Esparza; Inés Ruiz-Barranco; Elena Carrillo; María Soledad Arellano; Domingo Díaz-Díaz; Beatriz Hurtado; Andoni García-Muñoz; María Ángeles Relucio; Manuel Quintana-Díaz; María Rosario Úrbez; Andrés Saravia; María Victoria Bonan; Francisco García-Río; María Luisa Testillano; Jesús Villar; Abelardo García de Lorenzo; José Manuel Añón Journal: Sci Rep Date: 2022-05-13 Impact factor: 4.996
Authors: Sarah Wulf Hanson; Cristiana Abbafati; Joachim G Aerts; Ziyad Al-Aly; Charlie Ashbaugh; Tala Ballouz; Oleg Blyuss; Polina Bobkova; Gouke Bonsel; Svetlana Borzakova; Danilo Buonsenso; Denis Butnaru; Austin Carter; Helen Chu; Cristina De Rose; Mohamed Mustafa Diab; Emil Ekbom; Maha El Tantawi; Victor Fomin; Robert Frithiof; Aysylu Gamirova; Petr V Glybochko; Juanita A Haagsma; Shaghayegh Haghjooy Javanmard; Erin B Hamilton; Gabrielle Harris; Majanka H Heijenbrok-Kal; Raimund Helbok; Merel E Hellemons; David Hillus; Susanne M Huijts; Michael Hultström; Waasila Jassat; Florian Kurth; Ing-Marie Larsson; Miklós Lipcsey; Chelsea Liu; Callan D Loflin; Andrei Malinovschi; Wenhui Mao; Lyudmila Mazankova; Denise McCulloch; Dominik Menges; Noushin Mohammadifard; Daniel Munblit; Nikita A Nekliudov; Osondu Ogbuoji; Ismail M Osmanov; José L Peñalvo; Maria Skaalum Petersen; Milo A Puhan; Mujibur Rahman; Verena Rass; Nickolas Reinig; Gerard M Ribbers; Antonia Ricchiuto; Sten Rubertsson; Elmira Samitova; Nizal Sarrafzadegan; Anastasia Shikhaleva; Kyle E Simpson; Dario Sinatti; Joan B Soriano; Ekaterina Spiridonova; Fridolin Steinbeis; Andrey A Svistunov; Piero Valentini; Brittney J van de Water; Rita van den Berg-Emons; Ewa Wallin; Martin Witzenrath; Yifan Wu; Hanzhang Xu; Thomas Zoller; Christopher Adolph; James Albright; Joanne O Amlag; Aleksandr Y Aravkin; Bree L Bang-Jensen; Catherine Bisignano; Rachel Castellano; Emma Castro; Suman Chakrabarti; James K Collins; Xiaochen Dai; Farah Daoud; Carolyn Dapper; Amanda Deen; Bruce B Duncan; Megan Erickson; Samuel B Ewald; Alize J Ferrari; Abraham D Flaxman; Nancy Fullman; Amiran Gamkrelidze; John R Giles; Gaorui Guo; Simon I Hay; Jiawei He; Monika Helak; Erin N Hulland; Maia Kereselidze; Kris J Krohn; Alice Lazzar-Atwood; Akiaja Lindstrom; Rafael Lozano; Beatrice Magistro; Deborah Carvalho Malta; Johan Månsson; Ana M Mantilla Herrera; Ali H Mokdad; Lorenzo Monasta; Shuhei Nomura; Maja Pasovic; David M Pigott; Robert C Reiner; Grace Reinke; Antonio Luiz P Ribeiro; Damian Francesco Santomauro; Aleksei Sholokhov; Emma Elizabeth Spurlock; Rebecca Walcott; Ally Walker; Charles Shey Wiysonge; Peng Zheng; Janet Prvu Bettger; Christopher Jl Murray; Theo Vos Journal: medRxiv Date: 2022-05-27
Authors: Bram M A van Bakel; Frederik M A van den Heuvel; Jacqueline L Vos; Hajar Rotbi; Esmée A Bakker; Robin Nijveldt; Dick H J Thijssen; Thijs M H Eijsvogels Journal: J Clin Med Date: 2022-02-19 Impact factor: 4.241